FDA Advisory Panel Endorses Galleri: 10-0 on Safety, 6-4 on Effectiveness, 7-2 on Benefit-Risk

FDA Advisory Panel Endorses Galleri: 10-0 on Safety, 6-4 on Effectiveness, 7-2 on Benefit-Risk

Update, September 23, 2026 (meeting day). The FDA's Molecular and Clinical Genetics Panel (MCGP) of the Medical Devices Advisory Committee met today and voted in favor on all three questions in GRAIL's premarket approval (PMA) for the Galleri multi-cancer early detection (MCED) blood test:

1. Reasonable assurance of safety: 10–0 in favor.
2. Reasonable assurance of effectiveness: 6–4 in favor — the closest call of the day.
3. Benefits outweigh risks for the proposed indication: 7–2 in favor, with 1 abstention.

STAT's Matthew Herper, reporting from the meeting: "A Food and Drug Administration advisory panel on Wednesday endorsed Galleri, a blood test designed by the biotech firm Grail to screen for multiple types of cancer, concluding that the benefits of the test outweighed its risks.¹" He adds the standard caveat: "The FDA is not obliged to follow the advice of these panels, but it often does."

The evidence the panel weighed (both published September 22, the day before the meeting):

• NHS-Galleri (NEJM, 142,250 randomized): missed its primary endpoint — no significant reduction in stage III/IV cancers across 12 prespecified types after 3 screening rounds (incidence rate ratio 1.03, 95% CI 0.92–1.15, P=0.63). Stage IV incidence was lower (IRR 0.86, 95% CI 0.74–1.00), and post hoc analyses showed more stage I/II diagnoses in the screened arm (RR 1.16, 95% CI 1.03–1.30).
• PATHFINDER 2 (Nature Medicine, 32,007 participants completing 12-month assessment): detection rate 0.54%, PPV 60.3%, NPV 99.2%, specificity 99.64%, sensitivity 39.3% for all cancers and 69.8% for the prespecified 12.

GRAIL's proposed indication: screening for early detection of multiple cancer types in adults 50+, plus prediction of Cancer Signal Origin when a signal is detected — with labeling precautions that Galleri does not replace recommended single-cancer screening and positive results require confirmatory diagnostics.

Where this leaves the story: the panel's endorsement (with a 6–4 effectiveness split reflecting the missed NHS-Galleri primary endpoint) sends a positive signal to the final PMA decision, which outside analysts around the meeting expected in late 2026–2027. Approval would be the first FDA authorization of an MCED screening test and the gateway to Medicare/insurer reimbursement for the $949 cash-pay test. The prior revision of this note recorded the run-up: FDA staff flagged no major concerns and the stock surged ~35% on Sept 21. Related: the ongoing watch on final NHS-Galleri mortality outcomes (nhs-galleri-trial-cancer-mortdata — NHS-Galleri mortality data release) remains the deeper question of whether early detection translates into lives saved.